This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1992 Feb;10(1):39-44.

Intravesical therapy: does it affect the natural history of superficial bladder cancer?

D L Lamm¹, J G Griffith

Affiliations

PMID: 1565903

Review

Intravesical therapy: does it affect the natural history of superficial bladder cancer?

D L Lamm et al. Semin Urol. 1992 Feb.

. 1992 Feb;10(1):39-44.

Authors

D L Lamm¹, J G Griffith

Affiliation

¹ Department of Urology, West Virginia University Health Science Center, Morgantown 26506.

PMID: 1565903

No abstract available

PubMed Disclaimer

Similar articles

The natural history of superficial bladder carcinoma.
Fitzpatrick JM. Fitzpatrick JM. Semin Urol. 1993 Aug;11(3):127-36. Semin Urol. 1993. PMID: 8210834 Review. No abstract available.
Intravesical therapy for superficial bladder cancer.
Malkowicz SB. Malkowicz SB. Semin Urol Oncol. 2000 Nov;18(4):280-8. Semin Urol Oncol. 2000. PMID: 11101091 Review.
[Treatment and follow-up of superficial bladder cancer].
Raitanen M. Raitanen M. Duodecim. 2002;118(9):903-9. Duodecim. 2002. PMID: 12238168 Review. Finnish. No abstract available.
Recurrent or aggressive bladder cancer. Indications for adjuvant intravesical therapy.
Badalament RA, Ortolano V, Burgers JK. Badalament RA, et al. Urol Clin North Am. 1992 Aug;19(3):485-98. Urol Clin North Am. 1992. PMID: 1636233 Review.
Management of superficial transitional cell carcinoma of the bladder.
Fleischmann J, Goldberg G. Fleischmann J, et al. Semin Urol. 1993 Nov;11(4):193-204. Semin Urol. 1993. PMID: 8290825 Review.

See all similar articles

Cited by

Genetic variants of MnSOD and GPX1 and susceptibility to bladder cancer in a Turkish population.
Kucukgergin C, Sanli O, Amasyalı AS, Tefik T, Seckin S. Kucukgergin C, et al. Med Oncol. 2012 Sep;29(3):1928-34. doi: 10.1007/s12032-011-0057-z. Epub 2011 Sep 9. Med Oncol. 2012. PMID: 21904836
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.
Zahoor H, Mir MC, Barata PC, Stephenson AJ, Campbell SC, Fergany A, Dreicer R, Garcia JA. Zahoor H, et al. Invest New Drugs. 2019 Dec;37(6):1231-1238. doi: 10.1007/s10637-018-00716-w. Epub 2019 Jun 24. Invest New Drugs. 2019. PMID: 31231785 Clinical Trial.
Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model.
Xiao Z, Hanel E, Mak A, Moore RB. Xiao Z, et al. Clin Med Insights Oncol. 2011;5:315-23. doi: 10.4137/CMO.S7658. Epub 2011 Sep 21. Clin Med Insights Oncol. 2011. PMID: 22084620 Free PMC article.
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Fujiyama C, Jones A, Fuggle S, Bicknell R, Cranston D, Harris AL. Fujiyama C, et al. Br J Cancer. 2001 Feb;84(4):558-64. doi: 10.1054/bjoc.2000.1641. Br J Cancer. 2001. PMID: 11207054 Free PMC article.
Thiotepa versus Bacille Calmette-Guérin in Non-Muscle Invasive Bladder Cancer.
Fallah F, Fallah M, Sajadi Nia RS. Fallah F, et al. Curr Urol. 2013 Jan;6(3):160-4. doi: 10.1159/000343532. Epub 2012 Dec 21. Curr Urol. 2013. PMID: 24917736 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information